Compilation: Tan Xin
Huayu News, according to the South American Overseas Chinese News Network Compilation reported that the director of the Chilean Institute of Immunology and Immunotherapy (IMII), and Beijing Science and Technology Corporation (Sinovac) new crown vaccine in the Chilean phase III clinical trial Dr. Alexis Kalergis (Alexis Kalergis) said on January 26 that the results of Coxing vaccine trials in Chile so far are encouraging.
▲On January 14, medical staff in Taiyuan, Shanxi, China were vaccinated with the domestically-made new crown vaccine. (Photo of China News Network)
Chile’s Courier reported that as Coxing Vaccine was about to arrive in Chile, Paula Daza, Deputy Minister of Public Health of the Ministry of Health of Chile, joined the Coxing Vaccine in Dr. Callegis, Dr. Susan Bueno (Susan Bueno) and Dr. Katia Abarca (Katia Abarca) of the Chile trial held a meeting to discuss the preliminary results of vaccine efficacy and safety, and said In these two aspects, the analysis results of the elderly over 60 years old and the adults under 60 years old are consistent.
Dr. Callegis pointed out after the meeting: "So far, the results of vaccine trials are encouraging. Regarding the quality of the vaccine, we evaluate its composition from the molecular and biochemical point of view.
vaccine efficacy and safety data It is also very good. There have been almost no adverse reactions so far...According to the preliminary test results we have obtained, we have conducted separate studies on the data of adults and the elderly. The two groups of data have the same conclusions regarding the efficacy and safety of the vaccine."
Specifically, regarding the safety of the vaccine, that is, whether it is tolerated or discomfort and adverse reactions occur, Dr. Abaka explained: “We found that there is almost no difference between adults under 60 years old and people over 60 years old. In some cases, the discomfort of the elderly over 60 years old was lower... In fact, none of the participants had a fever. The most common reaction was arm pain, but it was milder, usually lasting 1 to 2 days, and other symptoms were also All are mild and have a short duration. So we can say that the safety of vaccines we have seen so far is very good."
is aimed at vaccine efficacy,Dr. Bueno explained: “We have been testing whether (vaccinators) will produce antibodies to Spike protein, a constituent protein of the new coronavirus. Among the testers of adults under 60 and seniors over 60, we are all This antibody was successfully detected. The news is encouraging. We must do more tests and increase the number of testers." In addition, they also conduct other important tests to determine whether the vaccinators produce antibodies to other constituent proteins of the new coronavirus. A more complete immune response.
It is understood that Chilean President Sebastián Piñera stated on January 22 that the first batch of approximately 2 million doses of Coxing vaccine is expected to arrive in Chile on January 28, and the second batch of approximately 200 Ten thousand doses of vaccine are expected to arrive on January 31. (Original title: Chilean expert talks about Coxing vaccine: initial test results are encouraging)
.
